Newer in vivo technologies like kinematic motion analysis can add tremendous value to datasets that evaluate the efficacy of novel therapies. Our data suggests that neuropathic pain is a more profound condition than just hypersensitivity or abnormal sensory response. Expanding the examination to include broader endpoints may help understand possible side effects of new drugs.

This webinar reviews standard neuropathic pain models and readouts and includes fine motor kinematic analysis to highlight gait changes.


  • Antti Nurmi, PhD, Interim Managing Director, Charles River